DXR

Daxor (DXR)

Daxor Corporation

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:DXR

1 2 3 4 5 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/04/16	21:00	GlobeNewswire Inc.	New Studies Prove the Clinical Benefits of Daxor’s Blood Volume (BVA-100TM) Diagnostic In Ambulatory Heart Failure Patients For Measurement of Congestion	NASDAQ:DXR	Daxor Corporation
2024/04/15	21:00	GlobeNewswire Inc.	DAXOR CORPORATION TO EXHIBIT AT THE MEDAXIOM CARDIOVASCULAR TRANSFORUM CONFERENCE SPRING’24 TO ADVANCE AWARENESS AND FURTHER ADOPTION OF DAXOR’S BLOOD VOLUME DIAGNOSTIC (BVA-100™)	NASDAQ:DXR	Daxor Corporation
2024/04/10	21:00	GlobeNewswire Inc.	Daxor Corporation Announces New Hospital Account at Leading Chicago Hospital	NASDAQ:DXR	Daxor Corporation
2024/04/01	21:00	GlobeNewswire Inc.	Daxor Corporation to Exhibit at the American College of Cardiology for ACC.24	NASDAQ:DXR	Daxor Corporation
2024/03/25	21:00	GlobeNewswire Inc.	Daxor Corporation Acquires Volumex® and Megatope® From Its Existing Supplier Along With Glofil® to Enhance Existing Suite of Diagnostics	NASDAQ:DXR	Daxor Corporation
2024/03/22	21:00	GlobeNewswire Inc.	Daxor Corporation to Hold Investor Call Discussing Fiscal Year 2023 Financial Results and Corporate Update on March 25, 2024	NASDAQ:DXR	Daxor Corporation
2024/03/19	03:18	GlobeNewswire Inc.	Daxor Corporation Reports Increase in NAV to $7.08 Per Share and 31.8 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2023	NASDAQ:DXR	Daxor Corporation
2024/03/19	03:18	GlobeNewswire Inc.	Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders	NASDAQ:DXR	Daxor Corporation
2024/03/11	21:00	GlobeNewswire Inc.	Daxor Announces Sales to Three New Hospitals Furthering Expansion of Its User Base	NASDAQ:DXR	Daxor Corporation
2024/03/09	03:49	Edgar (US Regulatory)	Form NT-NCSR/A - Notice under Exchange Act Rule 12b-25 of inability to timely file Form N-CSR (annual or semi-annual report): [Amend]	NASDAQ:DXR	Daxor Corporation
2024/03/08	22:00	GlobeNewswire Inc.	Multi-Center Study Presented by Duke at Heart Failure Therapeutics Conference Highlights Daxor’s Unique Clinical Utility for Heart Failure Patients	NASDAQ:DXR	Daxor Corporation
2024/03/07	06:18	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:DXR	Daxor Corporation
2024/03/01	07:28	Edgar (US Regulatory)	Form NT-NCSR/A - Notice under Exchange Act Rule 12b-25 of inability to timely file Form N-CSR (annual or semi-annual report): [Amend]	NASDAQ:DXR	Daxor Corporation
2024/03/01	06:15	Edgar (US Regulatory)	Form NT-NCSR - Notice under Exchange Act Rule 12b-25 of inability to timely file Form N-CSR (annual or semi-annual report)	NASDAQ:DXR	Daxor Corporation
2024/02/26	22:00	GlobeNewswire Inc.	Daxor Corporation to Exhibit at the Technology and Heart Failure Therapeutics Conference	NASDAQ:DXR	Daxor Corporation
2024/02/12	22:00	GlobeNewswire Inc.	Daxor Corporation Starts 2024 with Ongoing Growth in New Blood Volume Analyzer Acquisitions	NASDAQ:DXR	Daxor Corporation
2024/02/07	22:00	GlobeNewswire Inc.	Daxor Corporation Closes Q4 2023 with Growth in New Sales to Hospital Systems and Increased Utilization of its BVA-100® Blood Volume Diagnostic Across the U.S. at Existing Accounts	NASDAQ:DXR	Daxor Corporation
2024/01/29	22:00	GlobeNewswire Inc.	Daxor Corporation to Exhibit at the Society of Nuclear Medicine and Molecular Imaging Mid-Winter and American College Nuclear Medicine Annual Meeting	NASDAQ:DXR	Daxor Corporation
2024/01/16	22:00	GlobeNewswire Inc.	Daxor Corporation to Exhibit at the Society for Critical Care Medicine 2024 Critical Care Congress	NASDAQ:DXR	Daxor Corporation
2024/01/09	22:00	GlobeNewswire Inc.	DAXOR AWARDED ADDITIONAL NEW PATENT FOR SMART BLOOD VOLUME GUIDANCE TECHNOLOGY TO IMPROVE TREATMENT AND OUTCOMES	NASDAQ:DXR	Daxor Corporation
2024/01/02	22:52	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:DXR	Daxor Corporation
2024/01/02	22:30	GlobeNewswire Inc.	Daxor Corporation Submits Dual 510(k)/CLIA-waiver Application to the FDA for Its Advanced Next-Generation Blood Volume Analyzer	NASDAQ:DXR	Daxor Corporation
2023/12/07	05:48	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:DXR	Daxor Corporation
2023/12/02	11:00	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:DXR	Daxor Corporation
2023/12/02	11:00	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:DXR	Daxor Corporation
2023/12/02	10:58	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:DXR	Daxor Corporation
2023/12/02	10:58	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:DXR	Daxor Corporation
2023/11/27	20:03	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:DXR	Daxor Corporation
2023/11/25	03:53	Edgar (US Regulatory)	Form NPORT-P - Monthly Portfolio Investments Report on Form N-PORT (Public)	NASDAQ:DXR	Daxor Corporation
2023/11/25	01:32	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:DXR	Daxor Corporation